Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.
The ATLANT study is prospective, multicentre, non-interventional, observational study. Patients with HR+/HER2-negative metastatic breast cancer received abemaciclib as monotherapy or in combination with endocrine therapy.
HR+/HER2- Breast Cancer|Metastatic Disease|–êdvanced Disease
DRUG: Abemaciclib|DRUG: Abemaciclib|DRUG: Abemaciclib
Progression-free Survival (PFS) of patients receiving abemaciclib, Progression-free Survival (PFS) of patients receiving abemaciclib in combination with endocrine therapy

Progression-free Survival (PFS) of patients receiving abemaciclib as a single agent, Up to 5 years
Overall Response Rate (ORR), ORR is defined as the proportion of patients with best overall response of CR or PR according to RECIST 1.1., Up to 5 years|Time To Chemotherapy (TTC), TTC is defined as the time from date of start of treatment to the date of the first documented chemotherapy, Up to 5 years|Time To New Treatment Options (TTN), TTN s defined as the time from date of start of treatment to the date of the first new New Treatment Options, Up to 5 years|Frequency of AE/SAE, occurenec of AE/SAE during therapy, Up to 5 years
The ATLANT study is prospective, multicentre, non-interventional, observational study.

136 patients with HR+/HER2-negative metastatic breast cancer received abemaciclib as monotherapy or in combination with endocrine therapy in different line therapy.

The purpose of this study is to better understand how abemciclib combinations are used in real-life conditions and their clinical impact for the treatment of Russian patients affected by (HR+)/ (HER2-) advanced breast cancer (ABC) or metastatic breast cancer (MBC).